Author: Formiga, Fabio Rocha; Leblanc, Roger; de Souza Rebouças, Juliana; Farias, Leonardo Paiva; de Oliveira, Ronaldo Nascimento; Pena, Lindomar
Title: Ivermectin: An award-winning drug with antiviral expectations against COVID-19 Cord-id: roe6g61u Document date: 2020_10_7
ID: roe6g61u
Snippet: Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenge
Document: Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns.
Search related documents:
Co phrase search for related documents- acute sars infection lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute sars infection lung injury prevent and lung injury: 1
- adjuvant role and lung injury: 1, 2
- low airway and lung airway: 1, 2
- low airway and lung injury: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date